Seeger Weiss Blog
Seeger Weiss Blog: Legal News and Analysis

Category : actos

FDA Delays Decision on Actos Replacement

May 3rd, 2012

Last week, Japan-based Takeda Pharmaceutical Co Ltd, makers of the drug Actos, announced that the FDA will extend its review of the company’s drug alogliptin. Alogliptin, a diabetes medication, was expected to be the successor to Takeda’s top-selling drug Actos. Before Takeda lost its patent protection on Actos, the type-2 diabetes treatment had been linked to an increased risk of bladder cancer in studies. In response, the FDA issued a warning to doctors who prescribed Actos to patients.

Seeger Weiss LLP, a national plaintiffs’ law firm, has been actively investigating the link between Actos and bladder cancer. If you believe you or someone you know developed bladder cancer as a result of taking Actos, the firm’s drug injury practice will review your case for free. Contact them here.


Bloomberg: 10,000 Actos Cancer Claims in U.S.

December 1st, 2011

A major report published by Bloomberg Businessweek today found that Takeda Pharmaceuticals, the manufacturers of the drug Actos, could face as many as 10,000 drug injury lawsuits in the United States. The claimants allege that the diabetes medication caused them to develop bladder cancer. In fact, the number of drug injury suits involving Actos being brought to court has become so massive that a group of judges is being polled to decide whether or not to consolidate the litigation. Learn more about the link between Actos and bladder cancer.

In a legal environment like this one, victims of Actos drug injury need an experienced and dedicated law firm in their corners in order to ensure their claims receive the attention they deserve. If you or someone you know has suffered complications as a result of taking Actos, contact Seeger Weiss LLP today. An attorney with our award-winning drug injury class action practice will assist you in evaluating your claim. Attorney consultations incur no obligation on your part and all initial consultations are free of charge. Seeger Weiss LLP has office locations in New York, New Jersey, Pennsylvania and California.


Drug Injury Claims Cause Actos Sales to Plunge

November 4th, 2011

Reports surfaced early today that profits for Japan-based Takeda Pharmaceutical Co. have substantially declined. One factor that several news sources, including Bloomberg Businessweek, have attributed to the company’s losses is the controversy surrounding its top-selling drug, Actos. Calls for the FDA to release cautionary warnings for the diabetes medication began to emerge after it was linked to an increased risk of bladder cancer. Takeda projects that its net income will plunge by over 30 percent over the course of the next four months.

Seeger Weiss’ highly experienced drug injury practice is closely monitoring reports of bladder cancer associated with Actos. To learn more, visit our Actos investigation page.


Drug Injury Specialists Warn of Actos Side Effects

October 31st, 2011

Following negative media attention and a swarm of recent pharmaceutical drug litigation involving the medication, the European Commission has requested that the European Medicines Agency (EMA) clarify its position on the use of Actos. Both France and Germany prohibited the diabetes drug after reports indicated that it increased patients’ risk of heart attack and bladder cancer. Although the FDA did not officially ban Actos in the U.S., it added warnings to its label. Now, the EMA has asserted that while the drug can be a “valid treatment” for type 2 diabetes, it should only be prescribed when other medications have failed. Furthermore, the agency urges doctors who prescribe Actos to closely monitor their patients. Read the full story.

The experienced pharmaceutical injury attorneys in Seeger Weiss’ drug injury practice are closely following developments about reported Actos side effects. To learn more, visit our Actos Investigation Page.